Synthetic speed

Vaxxilon AG is developing synthetic carbohydrate vaccines for bacterial infections that are designed to be quicker and less expensive to manufacture, and easier to store than traditional conjugate vaccines.

“It’s an order of magnitude different in terms of capital investment and potentially time,” Vaxxilon CEO Tom Monroe told BioCentury...